Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of Apatinib in Small Cell Lung Cancer patients who failed from Two or More Lines of Chemotherapy

Trial Profile

Efficacy and safety of Apatinib in Small Cell Lung Cancer patients who failed from Two or More Lines of Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Oct 2018 New trial record
    • 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top